Latest Breaking News On - Apellis pharmaceuticals inc - Page 6 : comparemela.com

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Adamj townsendPascal deschateletsApellis pharmaceuticals incApellis pharmaceuticalsJefferies financial groupNews ratings for apellis pharmaceuticals dailySecurities exchange commissionJpmorgan chase coApellis pharmaceuticals stock downEarnings history for apellis pharmaceuticalsNeedham companyGet free reportPharmaceuticals stock downExchange commissionFinancial groupApellis pharmaceuticals daily

UBS Group Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $85 00

UBS Group Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $85 00
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United statesAdamj townsendRobertw bairdA sinclair dunlopRaymond jamesCharles schwab investment management incApellis pharmaceuticalsNeedham companyProfund advisorsApellis pharmaceuticals stock downSecurities exchange commissionApellis pharmaceuticals incNews ratings for apellis pharmaceuticals dailyAmerican investors coAnalyst recommendations for apellis pharmaceuticalsWynnefield capital inc

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Q1 2024 Earnings Call Transcript

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

United statesTim sullivanRaymond jamesPhil ferroneTazeen ahmadCedric francoisAnupam ramaYigal nochomovitzJon millerSteve seedhouseCaroline baumalPriyanka groverJonathan millerMadam townsendSalveen richterMeredith kaya

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Holdings Decreased by Lisanti Capital Growth LLC

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Holdings Decreased by Lisanti Capital Growth LLC
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Cedric francoisAdamj townsendRaymond jamesFiera capital corpJennison associatesApellis pharmaceuticalsLisanti capital growthNews ratings for apellis pharmaceuticals dailyApellis pharmaceuticals incQuarter for apellis pharmaceuticalsExchange commissionApellis pharmaceuticals price performanceVanguard group incPolar capital holdings plcFree reportCapital growth

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® $25.6 million for EMPAVELI® Anticipates CHMP opinion for pegcetacoplan.

United statesPhilip ferroneMeredith kayaLissa pavlukCedric francoisExchange commission onApellis pharmaceuticals incAdvisory committee on immunization practicesEuropean unionExchange commissionEuropean medicines agencyNocturnal hemoglobinuriaSenior convertible notesSafety informationRetinal detachmentsRetinal vascular occlusion